Healthcare / Medical Instruments & SuppliesShanghai
$47.81
+0.39 (+0.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-12.5M · quality 46.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.8B
P/E
21.2x
↑EV/EBITDA
9.3x
↓ROE
5.6%
↑Gross Margin
50.9%
↑Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-35.6%
FCF CAGR
—
FCF margin
-1.4%
FCF / Net income
-0.06x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $905.3M · net income $220.2M · FCF $-12.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $905.3M | $905.3M | $866.6M | $754.7M | $3.39B |
| Net Income | $220.2M | $220.2M | $302.5M | $180.6M | $1.18B |
| EBITDA | $293.6M | $293.6M | $380.5M | $238.5M | $1.44B |
| EPS | 2.78 | 2.78 | 3.82 | 2.28 | 14.95 |
| Gross Margin | 50.9% | 50.9% | 55.7% | 48.8% | 59.9% |
| Operating Margin | 22.9% | 22.9% | 31.8% | 15.6% | 47.2% |
| Net Margin | 24.3% | 24.3% | 34.9% | 23.9% | 35.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
| Current Ratio | 12.36 | 12.36 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.5M | $-12.5M | $108.9M | $-508.7M | $1.09B |
| Returns | |||||
| ROE | 5.6% | 5.6% | 7.8% | 4.7% | 28.4% |
| Valuation | |||||
| P/E | 21.25 | 21.25 | 16.41 | 29.73 | 4.79 |
| EV/EBITDA | 9.29 | 9.29 | 10.63 | 17.08 | 2.58 |
| P/B | 0.96 | 0.96 | 1.28 | 1.40 | 1.36 |
| Growth & Yield | |||||
| Revenue Growth | 4.5% | 4.5% | 14.8% | -77.7% | — |
| EPS Growth | -27.2% | -27.2% | 67.5% | -84.7% | — |
| Dividend Yield | 4.2% | 4.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
15.1%
EPS terminal req.
$4.24
Spread vs growth
-42.4%
5Y implied EPS CAGR
13.0%
EPS terminal req.
$5.13
Spread vs growth
-40.3%
10Y implied EPS CAGR
11.5%
EPS terminal req.
$8.27
Spread vs growth
-38.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.0%
Start / end P/E
16.5x → 17.2x
EPS bridge
3.82 → 2.78
Residual
-1.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.